Buradasınız

Anasayfa » Content

Meme Lezyonlarının Değerlendirilmesinde Tc-99m MIBI Sintimamografi: Histopatolojik Bulgularla Karşılaştırma

99mTc MIBI Scintimammography in The Evaluation of Breast Lesions: Correlation with Histological Findings

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2007

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
Scintimammography (SMG) is a non-invasive functional diagnostic modality in the evaluation of breast lesions. In this study we retrospectively evaluated the scintimammographic examinations of 27 women and compared them with histopathological results. A total of 29 breast lesions were found. Histopathology of these lesions showed that 13 were malignant and 16 were benign. SMG correctly identified 10 of 13 malignant lesions. However, there were 7 false positive and 3 false negative findings. The sensitivity and specificity of SMG in detecting breast cancer were 77% and 59% respectively. Our results suggest that SMG may be used as a complementary imaging method for evaluation of breast lesions.
Bookmark/Search this post with
Abstract (Original Language): 
Sintimamografi (SMG) meme lezyonlarını değerlendirmede kullanılan noninvaziv fonksiyonel bir görüntüleme yöntemidir. Bu çalışmada, 27 kadın hastanın SMG görüntülemelerini ve histopatolojik sonuçlarını karşılaştırmalı olarak geriye dönük değerlendirdik. Bu hastalarda toplam 29 meme lezyonu saptanmıştı. Histopatolojik olarak, lezyonların 13’ü malign, 16’sı ise benign olarak raporlanmıştı. SMG’de bu 13 malign lezyondan 10 tanesi doğru olarak saptanmakla birlikte, 3 lezyonda yanlış negatiflik ve 7/16 benign lezyonda ise yanlış pozitiflik ile karşılaştık. Buna göre SMG’nin meme kanseri tanısında duyarlılığı %77, özgüllüğü ise %59 olarak bulundu. Çalışmamızın sonuçları, SMG’nin meme lezyonlarının değerlendirilmesinde tamamlayıcı bir tanı yöntemi olarak kullanılabileceğini düşündürmektedir.
FULL TEXT (PDF): 
PDF icon arastirmax-meme-lezyonlarinin-degerlendirilmesinde-tc-99m-mibi-sintimamografi-histopatolojik-bulgularla-karsilastirma.pdf
  • 1
23-27
  • Turkish

REFERENCES

References: 

1. Habbema JD, van Oortmarssen GJ, van Putten DJ, Lubbe JT,
van der Maas PJ. Age specific reduction in breast cancer
mortality by screen: an analysis of the results of Health
Insurance Plan of greater New York study. J Natl Cancer Inst
1986;77:317–20.
2. Bird RE, Wallace TW, Yankaskas BC. Analysis of cancers
missed at screening mammography. Radiology 1992;184:613–
17.
3. Kopans DB. Positive predictive value of mammography. Am J
Roentgenol 1992;158:521–6.
4. Cutrone JA, Khalkhali I, Yospur LS et al. 99mTc-sestamibi
scintimammography for the evaluation of breast masses in
patients with radiographically dense breasts. Breast J 1999; 5:
383-8.
5. Kopans DB. The positive predictive value of mammography.
Am J Roentgenol 1992;158:521–6.
6. Schillaci O. Is there a clinical role for scintimammography in
breast cancer diagnosis? J Nucl Med. 2005;46:1571-3.
7. Taillefer R. Clinical Applications of 99mTc-Sestamibi
Scintimammography. Semin Nucl Med 2005;35:100-15.
8. Liberman M, Sampalis F, Mulder DS, Sampalis JS. Breast
cancer diagnosis by scintimammography: a meta-analysis and
review of the literature. Breast Cancer Research and
Treatment 2003;80:115–26.
9. Leidenius MHK, Leppanen EA, Tykka HT, et al. The role of
Tc99msestamibi scintimammography in combination with the
triple assessment of primary breast cancer. Eur J Surg Oncol
2002;28:108-12.
10. Waxman AD: The role of 99mTc methoxyisobutylisonitrile in
imaging breast cancer. Semin Nucl Med 1997;27:40-54.
11. Palmedo H, Schomburg A, Grunwald F, et al. Technetium-
99m-MIBI scintimammography for suspicious breast lesions.
J Nucl Med 1996;37:626-30.
12. Palmedo H, Biersack HJ, Lastoria S, et al.
Scintimammography with technetium-99m
methoxyisobutylisonitrile: results of a prosspective European
multicentre trial. Eur J Nucl Med 1998;25:375-85.
13. Mankoff DA, Dunnwald LK, Gralow JR, et al. Blood flow
and metabolism in locally advanced breast cancer: relationship
to responce to therapy. J Nucl Med 2002;43:500-9.
14. Molino A, Pavarana M, Micciolo R, et al. Comparative study
of clinical, pathological and biological characteristics of
sympttomatic versus asymptomatic breast cancers. Ann Oncol
2000;11:581-6.
15. Takamura Y, Miyoshi Y, Taguchi T, Noguchi S. Prediction of
chemotherapeutic response by technetium 99m-MIBI
scintimammography in breast carcinoma patients. Cancer
2001;92:232-9.
16. Mankoff DA, Dunnwald LK, Gralow JR, et al. Monitoring the
response of patients with primary breast cancer breast
carcinoma to neoadjuvant chemotherapy using [technetium
99m]-sestamibi scintimammography. Cancer 1999;85:2410-
23.
17. Del Vecchio S, Zannetti A, Aloj L et al. Inhibition of early
99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein
overexpression in untreated breast carcinoma. Eur J Nucl Med
Mol Imaging 2003;30:879–87.
18. Tofani A, Sciuto R, Semprebene A, et al. 99mTc-MIBI
scintimammography in 300 consecutive patients: factors that
may affect accuracy. Nucl Med Commun 1999;20:1113-21.
19. Dupont WD, Page DL. Risk factors for breast cancer in
women with proliferative breast disease. N Engl J Med
1985;312:146 –51.
20. Carter CL, Corle DK, Micozzi MS, et al. A prospective study
of the development of breast cancer in 16,692 women with
benign breast disease. Am J Epidemiol 1998;128:467–77.
21. Gadzala DE, Cederbom GJ, Bolton JS, et al. Appropriate
management of atypical ductal hyperplasia diagnosed by
stereotactic core needle breast biopsy. Ann Surg Oncol
1997;4:283–6.
22. Taillefer R, Robidoux A, Lambert R, et al. Technetium-99msestamibi prone scintimammography to detect primary breast
cancer and axillary lymph node involvement. J Nucl Med
1995;36:1758-65.

Thank you for copying data from http://www.arastirmax.com